A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis (Q82763063)
Jump to navigation
Jump to search
scientific article published on 06 December 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis |
scientific article published on 06 December 2010 |
Statements
A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis (English)
Timothy L Vollmer
Daniel R Wynn
M Shamsul Alam
Joaquin Valdes
6 December 2010